Malignant Skin Neoplasm
6
2
3
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
16.7%
1 terminated out of 6 trials
50.0%
-36.5% vs benchmark
17%
1 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
At-Home Dermoscopy Artificial Intelligence
Optical Imaging Scans for the Diagnosis of Skin Cancer in Patients With Lesions
Prophylactic LYMphatic Reconstruction (LYMbR) to Prevent Lymphedema After Node Dissection for Cutaneous Malignancies
Website Application Based Education and Text Messaging in Improving Skin Wound Care in Patients Undergoing Mohs Surgery